揭开障碍:通过定性镜头探索伊朗的物质使用障碍治疗政策
Saeid Mirzaei1, Vahid Yazdi-Feyzabadi2, Mohammad Hossein Mehrolhassani3
1Non Communicable Diseases Research Center, Bam University of Medical Sciences, Sardaran Shahid Square-Shahid Rajaei Boulevard, Bam, 7616913555, Iran.
Addiction science & clinical practice
|November 13, 2024
概括
伊朗 伊朗 伊朗 伊朗
科学领域:
- 公共卫生 公共卫生
- 卫生政策 卫生政策
- 成 药物 药物 药物 药物
背景情况:
- 药物使用障碍 (SUD) 是一个全球性的健康问题,有不同的政策反应.
- 自1979年以来,伊朗实施了各种策略来管理SUD.
- 了解这些政策及其挑战对于有效的干预至关重要.
研究的目的:
- 描绘伊朗SUD治疗政策的演变.
- 确定这些政策实施中的固有挑战.
- 为伊朗的SUD提供未来基于证据的政策制定信息.
主要方法:
- 使用文档分析和半结构面试进行的定性研究.
- 审查了22份文件,并与政策制定者和实施者进行了32次采访.
- 使用传统的内容分析来解释数据.
主要成果:
- 伊朗南方民主联盟的政策从"道德模式" (1979-1993) 演变为"疾病模式" (1993年至今).
- 主要挑战包括过时的法律,政策矛盾,缺乏基于证据的方法和分散的观点.
- 实施了"疾病模型",强调禁欲,表明部分理解.
结论:
- 分散的权威和个人偏好阻碍了伊朗有效制定南方发展政策.
- 建议转向以证据为基础的政策制定,远离"道德模式".
- 更多地依赖科学证据对于开发强大的SUD治疗策略至关重要.
关键词:
疾病模型的疾病模型.减少伤害 减少伤害伊朗 伊朗 伊朗 伊朗这是一个道德模型,一个道德模型.政策分析 政策分析定性研究是一种定性研究.滥用物质滥用物质滥用物质滥用物质滥用物质滥用物质治疗方法 治疗方法战争对毒品的战争更多相关视频
相关概念视频
Substance Use Disorders Affecting Sleep
160
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
160
Drug Dependence
979
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
979
Drug Abuse and Addiction: Pharmacological Phenomena
444
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
444
Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
Community Based Intervention
34
Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
34
Drug Control Governance: Regulatory Bodies and Their Impact
142
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
142


